Q-omics provides the consensus-scored BSX profile across patient tissues and cancer cell-line models. BSX expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, BSX is differentially expressed in 2, with the highest sampling consensus in HNSC. Additionally, BSX RNA expression shows 7,476 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight COAD, HNSC, and TGCT as cancer lineages where BSX shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BSX — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BSX survival associations across molecular data types. BSX RNA expression shows survival associations in the most cancer types (17), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BSX RNA expression–survival associations across cancer types. High BSX expression shows unfavorable associations in COAD, KIRC, LUAD, READ and GBM, but favorable associations in UCEC. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for BSX RNA expression.
This table summarizes BSX tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for BSX. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BSX shows higher tumor expression in HNSC and PRAD. The HNSC box plot shows higher BSX RNA expression in tumor versus normal tissue (log2 FC = +0.018, t-test p = .025).
This table shows molecular features associated with BSX in patient tissues and cancer cell lines. In patient samples, BSX shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, BSX RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and LARGE_INTESTINE.
